山西医科大学学报2011，Vol.42Issue(3)：220-222,3.DOI:10.3969/J.ISSN.1007-6611.2011.03.012
吉非替尼治疗老年晚期肺癌的临床观察
Clinical observation of gefitinib in the treatment of advanced lung cancer in elderly patients
王文璋 1王京凯 1王幼黎 1高举 1李娅娜1
作者信息
- 1. 中国航空工业中心医院胸外科,北京,100012
- 折叠
摘要
Abstract
Objective To explore the feasibility of gefitinib as a first-line drug for advanced lung cancer in elderly patients. Methods Fifteen elderly patients with advanced lung cancer confrimed by pathology or cytology were given orally gefitinib 250 mg once a day in initial treatment until death or tumor progression or withdrawal by intolerable reaction. Breast CT scan was performed before and after treatment once a month. The curative effect, disease control rate, median survival time and control of the related symptoms of 15 elderly patients with advanced lung cancer after treated with gefitinib were observed. Results Disease control rate( CR + PR )was 53.3％.Disease control rate( CR + PR + SD ) was 86.7％. The median time to progression ( TTP )was 5.4 months. The median survival time ( MS )was 11.1 months. Skin toxicity was the most common complication( 10 cases ). Conclusion Gefitinib as the first-line drug is effective and tolerable for advanced lung cancer in elderly patients.关键词
肺癌/吉非替尼/临床疗效分类
医药卫生引用本文复制引用
王文璋,王京凯,王幼黎,高举,李娅娜..吉非替尼治疗老年晚期肺癌的临床观察 [J].山西医科大学学报,2011,42(3):220-222,3.
